Jerusalem Pharmaceuticals Co. Ltd.

PLSE:JPH Stock Report

Market Cap: US$64.4m

Jerusalem Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Jerusalem Pharmaceuticals has been growing earnings at an average annual rate of 8.2%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 3.6% per year. Jerusalem Pharmaceuticals's return on equity is 6.2%, and it has net margins of 11%.

Key information

8.2%

Earnings growth rate

7.4%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate3.6%
Return on equity6.2%
Net Margin11.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jerusalem Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

PLSE:JPH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24374121
30 Jun 24385111
31 Mar 24386121
31 Dec 23407111
30 Sep 23439132
30 Jun 23448122
31 Mar 23458122
31 Dec 22467132
30 Sep 22468132
30 Jun 22478132
31 Mar 22477132
31 Dec 21467132
30 Sep 21414122
30 Jun 21404122
31 Mar 21373111
31 Dec 20364111
30 Sep 20365111
30 Jun 20355101
31 Mar 20356101
31 Dec 19345101
30 Sep 19324101
30 Jun 1932491
31 Mar 1931591
31 Dec 1831581
30 Sep 1832691
30 Jun 1828691
31 Mar 1830691
31 Dec 1730681
30 Sep 1728571
30 Jun 1730571
31 Mar 1728571
31 Dec 1626371
30 Sep 1624191
30 Jun 1624181
31 Mar 1624181
31 Dec 1526281
30 Sep 1526471
30 Jun 1526381
31 Mar 1526381
31 Dec 1424281
30 Sep 1424171
30 Jun 1422171
31 Mar 1421181
31 Dec 1322271

Quality Earnings: JPH has high quality earnings.

Growing Profit Margin: JPH's current net profit margins (11%) are lower than last year (20.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: JPH's earnings have grown by 8.2% per year over the past 5 years.

Accelerating Growth: JPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: JPH had negative earnings growth (-52.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7.5%).


Return on Equity

High ROE: JPH's Return on Equity (6.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies